Issue 26
Get instant access to latest e-book

latest news


May 2017

Novartis receives FDA approval for expanded use of Zykadia®

Novartis today announced the US Food and Drug Administration FDA approved the expanded use of Zykadia ceritinib to include the firstline treatment of patients with metastatic nonsmall cell lung cancer NSCLC whose tumors are anaplastic lymphoma kinase ALKpositive as detected by an FDAapproved test Zykadia…


May 2017

Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel

Kite Pharma Inc a leading cell therapy company announced that the US Food and Drug Administration FDA has accepted for priority review the Biologics License Application BLA for axicabtagene ciloleucel The submission follows positive data demonstrated with a single infusion of axicabtagene ciloleucel in the…


May 2017

Optum and Merck Collaborate to Advance Value-Based Contracting of Pharmaceuticals

Optum the health services business of UnitedHealth Group and Merck will collaborate to develop and simulate the performance of contractual reimbursement models in which payment for prescription drugs is aligned more closely with patient health outcomes Through a multiyear collaboration on a shared Learning Laboratory…

press releases


May 2017

Lupin Pharmaceuticals Inc. Announces a Nationwide Recall of MibelasTM 24 Fe (Norethindrone Acetate and Ethinyl Estradiol 1mg/0.02mg Chewable Tablets and Ferrous Fumarate 75mg) Tablets

Lupin Pharmaceuticals Inc announced today that it has voluntarily recalled lot L Exp of Mibelas Fe Norethindrone Acetate and Ethinyl Estradiol mg mg chewable and ferrous fumarate mg Tablets at…


May 2017

Neurana Pharmaceuticals Receives Notice of Allowance of Patents For Tolperisone, a Novel Skeletal Muscle Relaxant

Neurana Pharmaceuticals Inc a specialty pharmaceutical company focused on the development and commercialization of products that address unmet therapeutic needs of the central nervous system today announced receipt of a…


May 2017

Thermi® Receives Clearance to Market ThermiRF® in Brazil, the Second-Largest World Market for Aesthetic Treatments

The renowned and innovative aesthetic technology company Thermi an Almirall company announces regulatory clearance to market and distribute ThermiRF in Brazil ThermiRF is a temperaturecontrolled radiofrequency platform used for a…

Events


May 2017


May 2017

Market Access for Precision Medicine

Hanson Wade
Hyatt Regency Dulles


  • 3

    Parenteral Preparations

    INTRODUCTION Parenteral preparations are defined as solutions suspensionsemulsions for injection or infusion powders for injection or infusion gels for injecti..

Knowledge Bank

  • Interviews

    Datwyler Pharma Packaging

    Senior Manager Global Scientific Affairs
    Renaud Janssen PhD is the Senior Manager of Global Scientific Affairs at Datwyler Pharma Packaging He frequently presents on international conferences on subjects related to elastomeric and aluminiumplastic closures for pharmaceutical applications Re..

  • Articles

    The European Lead Factory

    In drug discovery the search for new chemical equity to be developed into valuable preclinical and clinical candidates is very time and costintensive This is a particular difficulty for academics or small and medium enterprises SMEs who are likely to have limited resources Additionally small companies are often created around a single compound or…

  • Techno Trends

    Evotec and Eternygen to Develop Novel Metabolic Disease Therapy

    Evotec and Eternygen announced a drug discovery collaboration to develop novel metabolic disease therapy The two companies will develop novel small molecule inhibitors against an Eternygen target to treat metabolic disease using Evotecs technology platform and broad expertise in drug discovery and preclinical development Eternygen is working on the sodium coupled citrate transporter NaCT a novel target which is a…

Editorial Section

  • Strategy

    Generics in Switzerland

    The article talks about the Swiss Generics market the penetration rate of generics in Switzerland why generics are a safe and smarter choice manufactured to modern standards with affordable prices and the threat of government forcing generic companies to benchmark…

  • Research development

    Biologics and Biosimilars

    With the early generation of biologics starting to lose patent protection the field of biosimilars too has been gaining attention Biosimilars are the generic version of a biologic drug developed for launch post the patent expiry of the original drug…

  • Clinical Trails

    Patient Recruitment

    To address the challenges faced in patient recruitment and retention in clinical trials innovative technologies are being utilised in AsiaPacific as well as other regions to optimise the processes involved From patient matching to improving the consent process technology has…

  • Expert Talk

    Biologics’ Drug Delivery Systems

    In this interview Peter Soelkner of Vetter discusses drug delivery trends for biologics and in particular prefilled syringes He offers insight into the advantages and challenges of this system for biologics important issues to consider…